-
公开(公告)号：KR101631243B1
公开(公告)日：2016-06-17
申请号：KR1020090041567
申请日：2009-05-13
Applicant: 신일제약주식회사
Abstract: 본발명은특정배합비율로구성된알렌드로네이트/키토산수용액과폴리메타크릴레이트/부탄올용액및 폴리비닐알콜/염화나트륨수용액을사용하여 W/O/W형에멀젼을간단한공정으로제조할수 있게함으로써, 알렌드로네이트의낮은생체이용률과위장관내 흡수율저하등의문제점을개선시킬수 있는새로운알렌드로네이트제제를제공할수 있게한 것이다.
-
2.发明公开
公开(公告)号：KR1020090117071A
公开(公告)日：2009-11-12
申请号：KR1020080042957
申请日：2008-05-08
Applicant: 신일제약주식회사
Abstract: PURPOSE: A nano pharmaceutical composition for preventing and treating bone disease containing alendronate of ion pair complexes is provided to improve bioavailability and treat gastrointestinal tract. CONSTITUTION: A nano pharmaceutical composition for preventing and treating bone disease contain oil soluble ion pair complex in which alendronate and cationoid reagent are bound. The cationoid reagent is carnitine salt, benzalkonium chloride, quaternary ammonium of cetrimid, arginine or lysine peptide. The nano particle further comprises oil soluble ion pair complex and mucosal adhesive polymer in the weight ratio of 1:0.05-10. A method for manufacturing the nano pharmaceutical composition comprises: a step of adding cationoid reagent to alendronate to produce oil soluble ion pair complex; a step of preparing suspension; a step of dissolving organic solvent in suspension to form primary emulsion of W/O type; and a step of adding emulsifier solution to the primary emulsion to form multiple emulsion of W/O/W type.
Abstract translation: 目的：提供用于预防和治疗含有离子对复合物的阿仑膦酸盐的骨病的纳米药物组合物，以提高生物利用度并治疗胃肠道。 构成：用于预防和治疗骨病的纳米药物组合物含有阿仑膦酸盐和阳离子试剂结合的油溶性离子对络合物。 阳离子型试剂是肉碱盐，苯扎氯铵，四氯化三铵，精氨酸或赖氨酸肽。 纳米颗粒还含有油溶性离子对复合物和粘膜粘合剂聚合物，重量比为1:0.05-10。 制备纳米药物组合物的方法包括：将阳离子试剂加入阿仑膦酸盐以产生油溶性离子对络合物的步骤; 制备悬浮液的步骤; 将有机溶剂溶解在悬浮液中形成W / O型初级乳液的步骤; 以及将乳化剂溶液加入到初级乳液中以形成W / O / W型多重乳液的步骤。
-
公开(公告)号：KR1020100122589A
公开(公告)日：2010-11-23
申请号：KR1020090041567
申请日：2009-05-13
Applicant: 신일제약주식회사
CPC classification number: A61K8/97 , A61K2800/522 , A61K2800/85 , A61Q19/08
Abstract: PURPOSE: A method for manufacturing a novel alendronate emulsion dry is provided to produce W/O/W type emulsion by simple process. CONSTITUTION: A method for manufacturing a novel alendronate emulsion dry comprises: a step of adding a solution containing 0.05-5 weight parts of alendronate and 0.05-5 weight parts of chitosan dissolved in 5-100 weight parts of water in a butanol solution in a volume ratio of 2:1-3:1 to prepare W/O type emulsion; a step of adding W/O type emulsion to a solution containing 0.5-2%(w/v) of polyvinyl alcohol solution and 0.7-1%(w/v) sodium chloride solution in a volume ratio of 2:1-10:3 to prepare W/O/W type emulsion; a step of compressing or concentrating the emulsion to remove butanol; a step of adding a solution containing 0.5-20%(w/v) of saccharide selected from a group consisting of mannitol, lactose and glucose in a volume ratio of 2:1-5:1; and a step of drying. A pharmaceutical composition for preventing and treating bone diseases contains alendronate emulsion dry as an active ingredient.
Abstract translation: 目的：提供一种制备新型阿仑膦酸盐乳液干燥的方法，通过简单的工艺生产W / O / W型乳液。 构成：制备新型阿伦膦酸酯乳液的方法包括：将溶于5-100重量份水中的0.05-5重量份阿仑膦酸盐和0.05-5重量份壳聚糖的溶液加入到丁醇溶液中的步骤 体积比为2：1-3：1，制备W / O型乳液; 将含有0.5-2％（w / v）聚乙烯醇溶液和0.7-1％（w / v）氯化钠溶液的溶液以体积比为2：1-10：1的溶液加入W / O型乳液的步骤： 3制备W / O / W型乳液; 压缩或浓缩乳液以除去丁醇的步骤; 添加体积比为2：1-5：1的含有选自甘露糖醇，乳糖和葡萄糖的0.5-20％（w / v）糖的溶液的溶液的步骤; 和干燥步骤。 用于预防和治疗骨疾病的药物组合物含有作为活性成分的阿仑膦酸盐乳液。
-
-
Search Results
3
records
(took 0.016 seconds)
